# US 2015/0104456 A1 · Antagonists of il-17 isoforms and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104456 A1
- Document ID: US20150104456A1
- Status: Published application
- Kind: A1
- Application number: 14/396,315
- Filed: 2013-06-11
- Published: 2015-04-16
- Earliest claimed: 2012-06-12
- Assignees: Orega Biotech
- Applicants: Orega Biotech
- Inventors: Gilles Alberici; Jeremy Bastid; Armand Bensussan; Nathalie Bonnefoy; Jean- Francois Eliaou
- Web page: https://patentgrep.com/patent/US20150104456A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.

## Claims

### Claim 1

A method for preventing or treating cancer in a patient comprising the step of administering to the patient a composition comprising at least one IL-17 antagonist of at least one IL-17 isoform, wherein the at least one IL-17 isoform is selected from the group consisting of IL-17B, IL-17C and IL-17D.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer, colon cancer, gastric cancer, glioma, hepatocellular carcinoma, kidney cancer, leukemia, lung cancer, lymphoma, melanoma, multiple myeloma, ovarian cancer, pancreatic cancer or prostate cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administering step thereby:
targets and/or kills cancer cells or cells at increased risk for becoming cancerous;
and/or
preventing prevents or treats tumor metastasis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition further comprises one IL-17 antagonist of another IL-17 isoform.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antagonist is also an antagonist of at least another IL-17 isoform.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises:
an antagonist of each IL-17 isoform; or
one antagonist of all the IL-17 isoforms.

### Claim 7 (depends on 1)

The method of claim 1, wherein the IL-17 antagonist is an antibody or an antigen binding antibody fragment.

### Claim 8 (depends on 1)

The method of claim 1, further comprising the step of administering a therapeutic agent, wherein the composition increases the effectiveness of the therapeutic agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the therapeutic agent is a chemotherapeutic agent.
